CoChat

Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation

Open access
Shen, Jenny I., Montez-Rath, Maria E., Lenihan, Colin R., Turakhia, Mintu P., Chang, Tara I., Winkelmayer, Wolfgang C. · 2015 · American Journal of Kidney Diseases
Cited by 135

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Background Although warfarin is indicated to prevent ischemic strokes in most patients with atrial fibrillation (AF), evidence supporting its use in hemodialysis is limited. Our aim was to examine outcomes after warfarin initiation, relative to no warfarin use, following incident AF in a large cohort of hemodialysis patients who had comprehensive prescription drug coverage through Medicare Part D. Study Design Retrospective observational cohort study. Setting & Participants Patients in the US Renal Data System undergoing maintenance hemodialysis who were newly diagnosed with AF in 2007-2011, with Medicare Part D coverage, who had no recorded history of warfarin use. Predictor Warfarin initiation, identified by a filled prescription within 30 days of the AF event. Outcomes Death, ischemic stroke, hemorrhagic stroke, severe gastrointestinal bleeding, and composite outcomes. Measurements HRs estimated by applying Cox regression to an inverse probability of treatment-and-censoring-weighted cohort. Results Among 12,284 patients with newly diagnosed AF, 1838 (15%) initiated warfarin within 30 days; however, ~70% discontinued its use within one year. In intention-to-treat analyses, warfarin use was marginally associated with a reduced risk of ischemic stroke (HR, 0.68; 95% CI, 0.47-0.99), but not with any of the other outcomes. In as-treated analyses, warfarin use was associated with reduced mortality (HR, 0.84; 95% CI, 0.73-0.97). Limitations Short observation period, limited number of non-fatal events, limited generalizability of results to more affluent patients. Conclusions In hemodialysis patients with incident AF, warfarin use was marginally associated with a reduced risk of ischemic stroke, and there was a signal towards reduced mortality in as-treated analyses. These results support clinical equipoise regarding the use of warfarin in HD patients and underscore the need for randomized trials to fill this evidence gap.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2015.05.019

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 135

Metadata

Authors
Shen, J. I., Montez-Rath, M. E., Lenihan, C. R., Turakhia, M. P., Chang, T. I., & Winkelmayer, W. C.
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2015-10
Volume
66
Issue
4
Pages
677-688
ISSN
0272-6386 (ISSN-L)
OpenAlex
W2161773758
Cited by
135
References
13
FWCI
14.28
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. https://app.cochat.ai/papers/10.1053/j.ajkd.2015.05.019
The paper
Shen, J. I., Montez-Rath, M. E., Lenihan, C. R., Turakhia, M. P., Chang, T. I., & Winkelmayer, W. C. (2015). Outcomes After Warfarin Initiation in a Cohort of Hemodialysis Patients With Newly Diagnosed Atrial Fibrillation. American Journal of Kidney Diseases. https://doi.org/10.1053/j.ajkd.2015.05.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.